Neuropsychopharmacology
July 7, 2026
Wojciech Pasławski, Daniel Doyon, Carl Johan Ekman et al.
Psilocybin is a rapid-acting antidepressant, but its mechanism of action in major depressive disorder remains unclear. In this secondary analysis of randomized, placebo-controlled trial with multimodal CSF and blood biomarker measurements, psilocybin selectively reduced CSF galanin and noradrenaline, implicating that normalization of these co-transmitters is a key pharmacodynamic signature.
JAMA Network Open
May 15, 2026
Hampus Yngwe, Pontus Plavén-sigray, Carl Johan Ekman et al.
1 citation
Importance: Psilocybin has been proposed as a rapid-acting antidepressant (onset 6 weeks), but evidence from randomized clinical trials remains limited, particularly in the broader major depressive disorder (MDD) population. Objective: To assess short-term and long-term antidepressant effects of psilocybin therapy in patients with MDD. Design, Setting, and Participants: This double-blind,...
BMC Medical Education
April 9, 2026
Nikita Sanati Morel, Dea Siggaard Stenbæk, Johan Lundberg et al.
Major depression is a prevalent condition among patients with life-threatening illnesses, such as cancer, and recent findings suggest that psilocybin may hold promising treatment potential. Contemporary trials of psilocybin generally employ a model that includes psychotherapeutic support consisting of preparation and integration sessions surrounding the dosing. However, there is limited...
Frontiers in Psychology
January 24, 2023
Maria Beckman, Stig Poulsen, Manoj K. Doss et al.
EDITORIAL article Front. Psychol., 23 January 2023Sec. Psychology for Clinical Settings Volume 14 - 2023 | https://doi.org/10.3389/fpsyg.2023.1121234